Ad­verum faces murky fu­ture af­ter re­view turns up deep­er safe­ty is­sues for gene ther­a­py

Three months af­ter re­veal­ing that a pa­tient lost sig­nif­i­cant vi­sion in one eye af­ter re­ceiv­ing its ex­per­i­men­tal gene ther­a­py, Ad­verum an­nounced it found the safe­ty is­sues were more wide­spread: Five of 12 pa­tients who re­ceived a high dose of the ther­a­py saw “sim­i­lar clin­i­cal­ly-rel­e­vant events.”

Three re­quired surgery on their treat­ed eye. And all 12 are be­ing rec­om­mend­ed “ag­gres­sive im­munomod­u­la­to­ry treat­ments” to pre­vent fur­ther in­jury.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER